Landmark phase 2 trials ZUMA-1, JULIET, and TRANSFORM demonstrated durable clinical benefit of CD19 directed CAR T-cell therapies in multiply R/R DLBCL [41]. Here, CD19 is linked to diffuse large B-cell lymphoma.